Literature DB >> 8143118

Molecular mechanisms of isoniazid: a drug at the front line of tuberculosis control.

Y Zhang1, D B Young.   

Abstract

The resurgence of tuberculosis and emergence of multidrug-resistant isolates has focused attention on the need for an improved understanding of molecular aspects of the disease, and for elucidation of the factors responsible for drug action and resistance. Recent research has probed the mechanism of action of isoniazid (INH), a key drug in the chemotherapy of tuberculosis.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8143118     DOI： 10.1016/0966-842x(93)90117-a

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN： 0966-842X            Impact factor:   17.079


  18 in total

1.  Oxidative stress response and its role in sensitivity to isoniazid in mycobacteria: characterization and inducibility of ahpC by peroxides in Mycobacterium smegmatis and lack of expression in M. aurum and M. tuberculosis.

Authors:  S Dhandayuthapani; Y Zhang; M H Mudd; V Deretic
Journal:  J Bacteriol       Date:  1996-06       Impact factor: 3.490

2.  Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice.

Authors:  L E Bermudez; K Nash; M Petrofsky; L S Young; C B Inderlied
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 3.  Future directions in the development of new antitubercular drugs. Where do we go from here?

Authors:  W W Yew; C H Chau
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

Review 4.  Pharmacokinetic factors in the modern drug treatment of tuberculosis.

Authors:  J G Douglas; M J McLeod
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

5.  In vitro activity of a novel antimycobacterial compound, N-octanesulfonylacetamide, and its effects on lipid and mycolic acid synthesis.

Authors:  N M Parrish; T Houston; P B Jones; C Townsend; J D Dick
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

6.  Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase.

Authors:  A'Lissa B Gerum; Jonathan E Ulmer; David P Jacobus; Norman P Jensen; David R Sherman; Carol Hopkins Sibley
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

7.  Interaction of wild type, G68R and L125M isoforms of the arylamine-N-acetyltransferase from Mycobacterium tuberculosis with isoniazid: a computational study on a new possible mechanism of resistance.

Authors:  Ricardo Martins Ramos; Janaína Menezes Perez; Luis André Baptista; Hermes Luís Neubauer de Amorim
Journal:  J Mol Model       Date:  2012-03-30       Impact factor: 1.810

8.  Effects of isoniazid on ultrastructure of Mycobacterium aurum and Mycobacterium tuberculosis and on production of secreted proteins.

Authors:  F Bardou; A Quémard; M A Dupont; C Horn; G Marchal; M Daffé
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

9.  Detection of a point mutation associated with high-level isoniazid resistance in Mycobacterium tuberculosis by using real-time PCR technology with 3'-minor groove binder-DNA probes.

Authors:  H Rogier van Doorn; Eric C J Claas; Kate E Templeton; Adri G M van der Zanden; Arianne te Koppele Vije; Menno D de Jong; Jacob Dankert; Ed J Kuijper
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

10.  Interpreting expression data with metabolic flux models: predicting Mycobacterium tuberculosis mycolic acid production.

Authors:  Caroline Colijn; Aaron Brandes; Jeremy Zucker; Desmond S Lun; Brian Weiner; Maha R Farhat; Tan-Yun Cheng; D Branch Moody; Megan Murray; James E Galagan
Journal:  PLoS Comput Biol       Date:  2009-08-28       Impact factor: 4.475
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.